MustGrow Biologics Corp. (“MustGrow” or the “Company”), a private agricultural biotech company developing and commercializing a portfolio of natural bio-pesticides and bio-fertilizers, is pleased to announce the closing of a non-brokered private placement (the “Offering”).  The Offering consists of 1,712,533 common shares of the Company at price of $0.70 per common share for gross proceeds of $1,198,773.

The net proceeds of the Offering will be used to accelerate research & development of the Company’s bio-pesticide & bio-fertilizer formulations and for working capital and general corporate purposes.  Research & development proceeds will be directed towards its patented mustard-derived signature products and its prospective suite of in-licensed natural biologics.


The common shares issued under the Offering have a hold period expiring four months plus one day following the closing of the Offering.

Post-closing, the Company now has 25.0 million basic common shares issued & outstanding and 36.9 million on a fully-diluted basis.

About MustGrow

MustGrow is an agricultural biotech company focused on developing and commercializing a portfolio of patented natural bio-pesticides and bio-fertilizers, including its patented signature mustard-derived biologics. Targeting the fruit and vegetable and the cannabis industries, MustGrow has designed a US EPA and Canadian PMRA approved organic solution that uses the mustard seed’s natural defense mechanisms to protect plants from pests and diseases.

To learn more, please contact the Company at 1 (306) 717-1128 or visit: www.mustgrow.ca

ON BEHALF OF THE BOARD

“Corey Giasson”

Director & CEO

Certain statements contained herein constitute forward-looking statements. Such forward-looking statements are subject to both known and unknown risks and uncertainties which may cause the actual results, performances or achievements of the Company to be materially different from any future results, performances or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company does not undertake any obligation to publicly update or revise any forward-looking statements.

Click here to see the educational profile for MustGrow Biologics and to request an investor presentation.

Source: mustgrow.ca

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced the Company will have senior management participating in the following virtual financial community conferences and events during December 2020 .

  • Roth Deer Valley Consumer Conference – December 9 th to 11 th , 2020
  • Cantor Fitzgerald 2020 Virtual Cannabis MSO Summit – December 15 th to 16 th , 2020
  • MKM Partners – The Road Ahead, Preparation for 2021 Conference – December 15 th to 16 th , 2020

For more information regarding upcoming Curaleaf financial community conference and event participation please visit the investor relations section of the company website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce the appointment of Dr. Joel Moody, MD, MPH, DTM&H, as a medical and clinical advisor to the Company to assist in the expansion of clinical studies in Canada and the clinical data analysis on the ongoing U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19.

“We would like to welcome Dr. Moody as a medical and clinical advisor to our team and we look forward to his contributions in our ongoing FDA Phase 3 clinical study as well as expanding our COVID-19 studies in Canada,” said Michael Frank, CEO of Revive. “Dr. Moody’s experience in clinical epidemiology, data analysis and research are key to our FDA Phase 3 study as we gather clinical data from patients enrolled.”

Keep reading... Show less

– FinCanna Capital Corp. (CSE:CALI) (OTCQB:FNNZF), based in Vancouver, BC today announced that Andriyko Herchak, CEO, will present live at VirtualInvestorConferences.com on December 3 rd .

Keep reading... Show less

First-of-its-kind trial in Canada will pave the way for expanded MDMA-assisted treatment to support patients with posttraumatic stress disorder

Keep reading... Show less

Multi-year partnership designates BioSteel as new official sports drink of Philadelphia 76ers team, Training Complex, and the presenting partner of 76ers Training Camp

BioSteel today announced a multi-year deal with the Philadelphia 76ers, making the sports hydration company the official sports drink of the team. BioSteel will also serve as a partner of the Philadelphia 76ers Training Complex, and the presenting partner for 76ers Training Camp, which begins next week.

Keep reading... Show less